The Enterprise Value as of June 2026 (TTM) for Taysha Gene Therapies, Inc. (TSHA) is 985.42M

According to Taysha Gene Therapies, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 985.42M. This represents a change of 11.91% compared to the average of 880.53M of the last 4 quarters.

Taysha Gene Therapies, Inc. (TSHA) Historical Enterprise Value (quarterly & annually)

How has TSHA Enterprise Value performed in the past?

The mean historical Enterprise Value of Taysha Gene Therapies, Inc. over the last ten years is 416.20M. The current 985.42M Enterprise Value has changed 23.58% with respect to the historical average. Over the past ten years (40 quarters), TSHA's Enterprise Value was at its highest in in the December 2025 quarter at 1.23B. The Enterprise Value was at its lowest in in the September 2020 quarter at -49759839.94.

Taysha Gene Therapies, Inc. (TSHA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Taysha Gene Therapies, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Taysha Gene Therapies, Inc. (TSHA) Average Enterprise Value

How has TSHA Enterprise Value performed in the past?

The current Enterprise Value of Taysha Gene Therapies, Inc. (TSHA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Taysha Gene Therapies, Inc. (TSHA) Enterprise Value vs. Peers

How is TSHA’s Enterprise Value compared to its peers?

Taysha Gene Therapies, Inc.’s Enterprise Value is less than Dianthus Therapeutics, Inc. (2.80B), greater than Sana Biotechnology, Inc. (737.35M), greater than Oculis Holding AG (442.83M), less than AnaptysBio, Inc. (2.45B), greater than BridgeBio Oncology Therapeutics Inc. (570.82M), greater than Immatics N.V. (800.42M), less than Xencor, Inc. (1.08B), less than Nektar Therapeutics (1.17B), less than Atai Beckley Inc. (1.40B), less than Enliven Therapeutics, Inc. (2.68B),

Build a custom stock screener for Taysha Gene Therapies, Inc. (TSHA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Taysha Gene Therapies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Taysha Gene Therapies, Inc. (TSHA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Taysha Gene Therapies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.